A Performance Evaluation of the Enlite 3 Sensor



Status:Not yet recruiting
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:14 - 75
Updated:4/21/2016
Start Date:January 2016
End Date:April 2016
Contact:Robin Mottackel, M.S.
Email:robin.e.mottackel@medtronic.com
Phone:818.576.4886

Use our guide to learn which trials are right for you!

The purpose of this study is to support the use of the Enlite 3 sensor in arm and thigh in
subjects age 14 - 75 years and provide additional characterization of the Enlite 3 sensor
performance in arm in subjects age 14 - 75 years.

The study is a multi-center, randomized, prospective single-sample correlational design
without controls.

Inclusion Criteria:

1. Subject is 14 - 75 years of age at time of screening.

2. A clinical diagnosis of type 1 or 2 diabetes for a minimum of 9 months duration as
determined via medical record or source documentation by an individual qualified to
make a medical diagnosis

3. Adequate venous access as assessed by investigator or appropriate staff

4. Subjects participating in the high and low glucose challenges must have an
established insulin carbohydrate ratio(s) and insulin sensitivity ratio. (The term
"established" refers to a ratio that has been previously defined and tested prior to
screening visit). Subjects without established ratios may participate under
observation only.

Exclusion Criteria:

1. Subject will not tolerate tape adhesive in the area of Enlite 3 Sensor placement as
assessed by qualified individual.

2. Subject has any unresolved adverse skin condition in the area of Enlite 3 Sensors or
device placement (e.g., psoriasis, rash, Staphylococcus infection)

3. Subject is actively participating in an investigational study (drug or device)
wherein they have received treatment from an investigational study (drug or device)
in the last 2 weeks

4. Subject is female and has a positive pregnancy screening test

5. Females of child bearing age and who are sexually active should be excluded if they
are not using a form of contraception deemed reliable by investigator.

6. Subject is female and plans to become pregnant during the course of the study

7. Subject has had a hypoglycemic seizure within the past 6 months.

8. Subject has had hypoglycemia resulting in loss of consciousness within the past 6
months prior to screening visit.

9. Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months
prior to screening visit.

10. Subject has a history of a seizure disorder.

11. Subject has central nervous system or cardiac disorder resulting in syncope.

12. Subject has a history of myocardial infarction, unstable angina, coronary artery
bypass surgery, coronary artery stenting, transient ischemic attack (TIA),
cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm
disturbances or thromboembolic disease.

13. Subject has a hematocrit(Hct) lower than the normal reference range.

14. Subject has a history of adrenal insufficiency
We found this trial at
2
sites
Renton, Washington 98057
Principal Investigator: Ronald Brazg, MD
Phone: 425-251-1720
?
mi
from
Renton, WA
Click here to add this to my saved trials
Walnut creek, California 94598
Principal Investigator: Mark Christiansen, MD
Phone: 925-930-7267
?
mi
from
Walnut creek, CA
Click here to add this to my saved trials